X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (99) 99
Publication (14) 14
Dissertation (2) 2
Book / eBook (1) 1
Book Chapter (1) 1
Conference Proceeding (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (46) 46
male (45) 45
index medicus (43) 43
aged (25) 25
middle aged (23) 23
female (22) 22
animals (21) 21
prostate cancer (14) 14
oncology (13) 13
neurosciences (12) 12
prostatic neoplasms - genetics (12) 12
risk (11) 11
article (10) 10
research (10) 10
adult (9) 9
aged, 80 and over (9) 9
polymorphism, single nucleotide (9) 9
prisoners of war (9) 9
abridged index medicus (8) 8
case-control studies (8) 8
health aspects (8) 8
treatment outcome (8) 8
urology & nephrology (8) 8
cancer (7) 7
double-blind method (7) 7
metaanalysis (7) 7
risk factors (7) 7
analysis (6) 6
aspirin (6) 6
aspirin - therapeutic use (6) 6
biochemistry & molecular biology (6) 6
cells (6) 6
clinical medicine (6) 6
drug therapy, combination (6) 6
genetic predisposition to disease (6) 6
genome-wide association study (6) 6
immunohistochemistry (6) 6
incidence (6) 6
journal article (6) 6
klinisk medicin (6) 6
mice (6) 6
multidisciplinary sciences (6) 6
polymerase chain reaction (6) 6
retrospective studies (6) 6
aspirin - adverse effects (5) 5
base sequence (5) 5
cardiac & cardiovascular systems (5) 5
care and treatment (5) 5
coronary vessels (5) 5
drug therapy (5) 5
epidemiology (5) 5
health risk assessment (5) 5
hemorrhage - chemically induced (5) 5
life sciences (5) 5
medical and health sciences (5) 5
medicin och hälsovetenskap (5) 5
medicine & public health (5) 5
medicine, general & internal (5) 5
myocardial infarction (5) 5
neoplasm staging (5) 5
platelet aggregation inhibitors - adverse effects (5) 5
platelet aggregation inhibitors - therapeutic use (5) 5
prevention (5) 5
prostatic neoplasms - epidemiology (5) 5
prostatic neoplasms - pathology (5) 5
science (5) 5
stroke (5) 5
surgery (5) 5
thrombosis (5) 5
time factors (5) 5
usage (5) 5
brain (4) 4
cancer and oncology (4) 4
cancer och onkologi (4) 4
cardiovascular disease (4) 4
cardiovascular diseases (4) 4
cell line (4) 4
clinical neurology (4) 4
clinical trials (4) 4
clopidogrel (4) 4
complications (4) 4
dk/atira/pure/researchoutput/pubmedpublicationtype/d016428 (4) 4
expression (4) 4
genes (4) 4
genetic aspects (4) 4
genetics & heredity (4) 4
genome-wide association (4) 4
genotype (4) 4
glutamic acid - metabolism (4) 4
heart attacks (4) 4
identification (4) 4
intervention (4) 4
medicine (4) 4
molecular sequence data (4) 4
morbidity (4) 4
mortality (4) 4
patients (4) 4
postoperative complications - epidemiology (4) 4
prostate (4) 4
research article (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2155 - 2166
Patients who had received a drug-eluting stent and then dual antiplatelet therapy for 12 months were randomly assigned to 18 more months of therapy or aspirin... 
TRIALS | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | MULTICENTER | CLOPIDOGREL | TICAGRELOR | THROMBOSIS | RATIONALE | PREVENTION | ASPIRIN | CLINICAL-OUTCOMES | Piperazines - administration & dosage | Prasugrel Hydrochloride | Thiophenes - adverse effects | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Aspirin - administration & dosage | Incidence | Time Factors | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Myocardial Ischemia - mortality | Thrombosis - prevention & control | Drug Therapy, Combination | Myocardial Ischemia - epidemiology | Platelet Aggregation Inhibitors - adverse effects | Drug-Eluting Stents | Drug Administration Schedule | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Myocardial Ischemia - therapy | Aged | Hemorrhage - chemically induced | Aggregation | Treatment outcome | Care and treatment | Usage | Blood platelets | Analysis | Drug-eluting stents | Dosage and administration | Cardiovascular diseases | Thrombosis | Health aspects | Blood clot | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Drug delivery | Patients | Bleeding | Clinical outcomes | Cerebrovascular system | Coronary vessels | Implants | Clopidogrel | Drug therapy | Stents
Journal Article
Journal of Investigative and Clinical Dentistry, ISSN 2041-1618, 08/2017, Volume 8, Issue 3, pp. e12232 - n/a
Aim The aim of the present study was to compare the accuracy of radiographic measurements for dental implants planning using cone‐beam computed tomography... 
accuracy | cone‐beam computed tomography | pre‐operative planning | dental implant | helical computed tomography | cone-beam computed tomography | pre-operative planning | CT imaging | Implant dentures | Analysis | Prisoners of war
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2015, Volume 66, Issue 15, pp. B29 - B29
  Background The PE Plus Post-Approval Study (PE Plus PAS) was designed to examine long-term outcomes among patients treated with advanced generation,... 
Cardiovascular | Internal Medicine | Stent (Surgery) | Prisoners of war | Angiogenesis inhibitors | Confidence intervals | Cardiovascular disease | Heart attacks | Angioplasty | Stents
Journal Article
Journal of investigative and clinical dentistry, 08/2017, Volume 8, Issue 3
The aim of the present study was to compare the accuracy of radiographic measurements for dental implants planning using cone-beam computed tomography (CBCT)... 
Animals | Swine | Dimensional Measurement Accuracy | Tomography, Spiral Computed | Dental Implantation, Endosseous - methods | Therapy, Computer-Assisted | Cone-Beam Computed Tomography
Journal Article
Journal Article
by Shen, JK and Tryon, DN and Myklak, KC and Alsyouf, MM and Peplinski, BS and Conceicao, C and Ruckle, HC and Baldwin, DD and Liu, LZQ and Johnson, LJ and Davenport, DL and Venkatesh, R and Soria, F and Morcillo, E and De la Cruz, J and Serrano, A and Rioja, J and Budia, A and Fernandez, T and Fernandez, I and Bachiller, J and Sanchez, FM and Lee, BR and Callaghan, C and Mandava, SH and Peralta, D and Bouljihad, M and Dash, SD and Liu, JL and Tarr, MT and Maddox, MM and Lai, WL and Jordão, RJ and Bandeira, RAST and Leite, KR and Miranda, EP and Srougi, M Miguel and Tefik, T and Seitz, C and Brehmer, M and Osther, P and Giusti, G and Rassweiler, JR and Grasso, MG and Preminger, GP and Pearle, MP and Traxer, OT and Lee, JW and Lee, MY and Oh, TH and Kwon, WA and Park, SC and Jeong, H J and Seo, I Y and Patankar, SBP and Smith, YS and Yallappa, S and Polson, P and Subramonian, K and Fukai, YF and Ishii, T and Igarashi, T and Lamb, BW and Lettin, J and Cook, J and Malik, S and Graham, S and Elhage, O and Sakellariou, C and Smith, Ra and Galustian, C and Dasgupta, P and Olweny, E and Zhang, Z and Haimovich, B and Kwon, YS and Lu, T and Fyfe-Kirschner, BFK and Kim, DSK and Choi, T and Yoo, KH and Jeon, S and Shahrour, K and Keck, R and Jankun, J and Ball, MW and Readal, NT and Gorin, MA and Pierorazio, PM and Allaf, ME and Kallidonis, P and Vasilas, M and Panagopoulos, VP and Amanatides, LA and Kyriazis, IK and Vrettos, T and Fligkou, F and Liatsikos, E and Lovegrove, CE and Novara, G and ...
Journal of Endourology, ISSN 0892-7790, 10/2015, Volume 29, Issue S1, pp. P1 - A457
Journal Article
Environmental Toxicology and Chemistry, ISSN 0730-7268, 02/2015, Volume 34, Issue 2, pp. 437 - 445
Journal Article
by Anand, Sonia S and Bosch, Jackie and Eikelboom, John W and Connolly, Stuart J and Diaz, Rafael and Widimsky, Peter and Aboyans, Victor and Alings, Marco and Kakkar, Ajay K and Keltai, Katalin and Maggioni, Aldo P and Lewis, Basil S and Störk, Stefan and Zhu, Jun and Lopez-Jaramillo, Patricio and O'Donnell, Martin and Commerford, Patrick J and Vinereanu, Dragos and Pogosova, Nana and Ryden, Lars and Fox, Keith A A and Bhatt, Deepak L and Misselwitz, Frank and Varigos, John D and Vanassche, Thomas and Avezum, Alvaro A and Chen, Edmond and Branch, Kelley and Leong, Darryl P and Bangdiwala, Shrikant I and Hart, Robert G and Yusuf, Salim and SALA, JORGELINA and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and SCHYGIEL, PABLO OMAR and CUNEO, CARLOS and LUQUEZ, HUGO and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and MONTANA, OSCAR and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and GARRIDO, MARCELO and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and DRAN, RICARDO DARIO and CARDONA, MARCELO and GUZMAN, RANDOLPH and GUZMAN, LUIS and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and NANI, SEBASTIAN and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and GONZALEZ COLASO, PATRICIA DEL CARMEN and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and ECTOR, BAVO and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and VRANCKX, PASCAL and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and INDIO DO BRASIL, CLARISSE and PRECOMA, DALTON and ABRANTES, JOSE ANTONIO and MANENTI, EULER and REIS, GILMAR and SARAIVA, JOSE and MAIA, LILIA and HERNANDES, MAURO and ROSSI, PAULO and ROSSI DOS SANTOS, FABIO and ... and COMPASS Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet, ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 219 - 229
Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | THERAPY | OUTPATIENTS | CARDIOVASCULAR EVENT RATES | PREVENTION | RISK | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Carotid Artery Diseases - complications | Male | Peripheral Arterial Disease - complications | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Lower Extremity - surgery | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Rivaroxaban - therapeutic use | Carotid Artery Diseases - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Peripheral Arterial Disease - drug therapy | Carotid Artery Diseases - epidemiology | Morbidity | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Peripheral Arterial Disease - epidemiology | Factor Xa Inhibitors - adverse effects | Aged | Myocardial Infarction - prevention & control | Amputation - statistics & numerical data | Hemorrhage - chemically induced | Lower Extremity - blood supply | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Heart attacks | Medical imaging | Mortality | Clinical trials | Cardiovascular disease | Patients | Disease control | Carotid arteries | Disease prevention | Coronary vessels | Blood pressure | Carotid artery | Acute coronary syndromes | Thromboembolism | Health risk assessment | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Amputation | Drug | drug therapy | chemically induced | complications | prevention & control | Peripheral Arterial Disease | etiology | Clinical Medicine | Myocardial Infarction | statistics & numerical data | blood supply | Carotid Artery Diseases | Platelet Aggregation Inhibitors | adverse effects | mortality | Lower Extremity | Dose-Response Relationship | therapeutic use | surgery
Journal Article
by Connolly, Stuart J and Eikelboom, John W and Bosch, Jackie and Dagenais, Gilles and Dyal, Leanne and Lanas, Fernando and Metsarinne, Kaj and O'Donnell, Martin and Dans, Anthony L and Ha, Jong-Won and Parkhomenko, Alexandr N and Avezum, Alvaro A and Lonn, Eva and Lisheng, Liu and Torp-Pedersen, Christian and Widimsky, Petr and Maggioni, Aldo P and Felix, Camilo and Keltai, Katalin and Hori, Masatsugu and Yusoff, Khalid and Guzik, Tomasz J and Bhatt, Deepak L and Branch, Kelley R H and Cook Bruns, Nancy and Berkowitz, Scott D and Anand, Sonia S and Varigos, John D and Fox, Keith A A and Yusuf, Salim and SALA, JORGELINA and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and SCHYGIEL, PABLO OMAR and CUNEO, CARLOS and LUQUEZ, HUGO and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and MONTANA, OSCAR and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and GARRIDO, MARCELO and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and DRAN, RICARDO DARIO and CARDONA, MARCELO and GUZMAN, RANDOLPH and GUZMAN, LUIS and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and NANI, SEBASTIAN and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and GONZALEZ COLASO, PATRICIA DEL CARMEN and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and ECTOR, BAVO and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and VRANCKX, PASCAL and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and INDIO DO BRASIL, CLARISSE and PRECOMA, DALTON and ABRANTES, JOSE ANTONIO and MANENTI, EULER and REIS, GILMAR and SARAIVA, JOSE and MAIA, LILIA and HERNANDES, MAURO and ROSSI, PAULO and ROSSI DOS SANTOS, FABIO and ZIMMERMANN, SERGIO LUIZ and RECH, RAFAEL and ... and COMPASS Investigators and COMPASS investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet, ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 205 - 218
Coronary artery disease is a major cause of morbidity and mortality worldwide, and is a consequence of acute thrombotic events involving activation of... 
PREVENTION | MEDICINE, GENERAL & INTERNAL | ORAL RIVAROXABAN | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Male | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Coronary Artery Disease - drug therapy | Morbidity | Factor Xa Inhibitors - therapeutic use | Factor Xa Inhibitors - adverse effects | Aged | Coronary Artery Disease - epidemiology | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Anticoagulants | Aspirin | Stroke | Heart attacks | Mortality | Coronary artery | Clinical trials | Cardiovascular disease | Coronary artery disease | Disease control | Disease prevention | Coronary vessels | Acute coronary syndromes | Thromboembolism | Health risk assessment | Drug therapy | Heart diseases | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Drug | drug therapy | chemically induced | prevention & control | Coronary Artery Disease | Clinical Medicine | Myocardial Infarction | Platelet Aggregation Inhibitors | adverse effects | mortality | Dose-Response Relationship | therapeutic use
Journal Article